Healthcare is an emotive issue and purchasing decisions cannot always be made purely on clinical outcome and costing criteria. To consider the impact of a technology on a patient’s quality of life in ameliorating the impact of a disease, is to consider health outcomes from a patient’s preferential perspective. CATALYST has considerable experience in designing, disseminating and delivering quality of life studies. Using standard gamble and time trade-off methodologies in addition to generic and disease-specific quality of life instruments, CATALYST has evaluated the outcomes in patients receiving different treatments in diverse diseases.